CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 23, 2007--Curis, Inc. (NASDAQ: CRIS), a drug development company focused on seeking to develop novel targeted medicines primarily for cancer treatment, will release its third quarter financial results on Tuesday, October 30, 2007 before the market opens. The Company will also hold a conference call on October 30, 2007 at 10:00 a.m. Eastern time to discuss its financial results, the progress of CUDC-101 and other multi-target inhibitors that Curis is developing under its Targeted Cancer Drug Development Platform, Curis' Hedgehog-based product development programs under collaboration with Genentech and Wyeth, as well as additional corporate activities. Daniel Passeri, President and Chief Executive Officer of Curis, will host the call.
To access the live conference call, please call (800) 329-9097 from the United States or Canada or (617) 614-4929 from other locations, shortly before 10:00 a.m. Eastern time. The conference ID number is 30281225. The conference call can also be accessed on the Curis website at www.curis.com in the Investors section. Replay will be available approximately two hours after the completion of the call and through 5:00 p.m., Tuesday, November 13, 2007. To access the replay, please call (888) 286-8010 from the United States or Canada or (617) 801-6888 from other locations and reference the conference ID number 48805608.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to create new medicines, primarily for cancer. In expanding its drug development efforts in the field of cancer through its Targeted Cancer Drug Development Platform, the Company is building upon its previous experiences in targeting signaling pathways in the areas of cancer, neurological disease and cardiovascular disease. For more information, visit www.curis.com.
CONTACT: Curis, Inc. Michael P. Gray, 617-503-6632 CFO & COO email@example.com SOURCE: Curis, Inc.